Q32 Bio (QTTB) Other financing activities (2018 - 2024)
Q32 Bio (QTTB) posted quarterly Other financing activities of $317000.0 for Q4 2024, up 317.11% year-over-year from $76000.0 in Q1 2024, and down 68.2% quarter-over-quarter from $997000.0 in Q3 2024.
Q32 Bio (QTTB) Other financing activities (2018 - 2024) Analysis & Trends
Q32 Bio's Other financing activities history runs 7 years deep, the most recent figure standing at $317000.0 for Q4 2024.
- In Q4 2024, Other financing activities rose 317.11% year-over-year to $317000.0; the TTM figure through Dec 2025 stood at $1.3 million (down 22.43% YoY), while the FY2024 annual figure was $1.7 million, up 1498.11% from the prior year.
- Other financing activities for Q4 2024 stood at $317000.0, down from $997000.0 in the prior quarter.
- The five-year high for Other financing activities was $51.8 million in Q4 2020, with the low at -$438000.0 in Q2 2022.
- The 5-year median for Other financing activities is $139000.0 (2020), against an average of $3.4 million.
- The sharpest annual moves came in 2021 and 2024: Other financing activities tumbled 3444.44% in 2021, then jumped 2433.33% in 2024.
- Q32 Bio's Other financing activities stood at $51.8 million in 2020, then tumbled by 98.69% to $681000.0 in 2021, then plunged by 164.32% to -$438000.0 in 2022, then soared by 117.35% to $76000.0 in 2023, then jumped by 317.11% to $317000.0 in 2024.
- Business Quant data shows QTTB's Other financing activities at $317000.0 in Q4 2024, $997000.0 in Q3 2024, and $380000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 317,000.00 |
| Dec 31, 2024 | 317,000.00 |
| Sep 30, 2024 | 997,000.00 |
| Sep 30, 2024 | 997,000.00 |
| Jun 30, 2024 | 380,000.00 |
| Jun 30, 2024 | 380,000.00 |
| Dec 31, 2023 | 76,000.00 |
| Dec 31, 2023 | 76,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Mar 31, 2023 | 15,000.00 |
| Mar 31, 2023 | 15,000.00 |
| Jun 30, 2022 | -438,000.00 |
| Jun 30, 2022 | -438,000.00 |
| Mar 31, 2022 | 439,000.00 |
| Mar 31, 2022 | 439,000.00 |
| Dec 31, 2021 | 681,000.00 |
| Dec 31, 2021 | 681,000.00 |
| Sep 30, 2021 | -301,000.00 |
| Sep 30, 2021 | -301,000.00 |